Search Results for: WLLW

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients, reported its first-quarter 2021 financial and operating results. Highlights from the report include the appointment of Dr. Mathias Schuetz to vice president and Dr. Trish Choudhary to vice president, research & development; the closing of its public offering, comprised of … Continue reading “QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Releases Q1 2021 Report, Business Updates”

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has completed a series of studies evaluating the safety and anti-inflammatory, anti-aging, and antimicrobial properties of its cannabigerol (“CBG”) when used on skin. The studies were conducted in collaboration with Signum Biosciences Inc., … Continue reading “QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Announces Completion of Groundbreaking Study on CBG Use on Skin”

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF) today announced its completion of the first commercial scale fermentation run of its first cannabinoid for market, cannabigerol (“CBG”). “We are very pleased with the yield and quality of our first commercial scale fermentation run of CBG,” said Trevor Peters, Willow’s president and chief executive officer. “I think it … Continue reading “QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Completes 1st Commercial Scale Fermentation Run of CBG”

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has announced its fourth-quarter and full-year numbers for the period ended Dec. 31, 2020. In the report, Willow noted that it had filed a short form base shelf prospectus that allowed the company … Continue reading “QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Releases Q4 and FY 2020 Financial, Operational Report”

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has released an update on the acceleration of common share warrants that was previously announced. Willow completed the acceleration, which was comprised of 9,320,478 common share purchase warrants issued on Oct. 29, 2020. The … Continue reading “QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Updates Status Regarding Acceleration of Expiry Date of Outstanding Warrants”

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF) has closed its previously announced upsized bought deal offering of 17,424,800 common shares of the company, each at a price of $1.65, including 2,272,800 common shares issued per the full exercise of the over-allotment option. Willow Biosciences secured aggregate gross proceeds of approximately $28.75 million in the offering, which … Continue reading “QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Secures $28.75M in Bought Deal Offering”

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, will exercise its right under the terms of an Oct. 29, 2020, warrant indenture to accelerate the expiry date of common share purchase warrants issued that same day. The warrant indenture stipulates that … Continue reading “QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Exercises Right to Accelerate Expiry Date of Outstanding 2020 Warrants”

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has made advancements on its work on a proprietary yeast strain for the production of Tetrahydrocannabinol (“THC”); the company also announced plans to commercially launch the product in the highly regulated, legal Canadian … Continue reading “QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Releases Update on THC, Plans for Canadian Market Launch”

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF) has contracted with a leading manufacturer to produce its first cannabinoid, cannabigerol (“CBG”); the first production run is slated for early 2021 and will result in commercial quantities of Willow’s ultra-pure CBG. The product will be manufactured in Europe. In addition, Willow announced plans to run a second 500-litre … Continue reading “QualityStocksNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Announces Progress in Commercialization Plan with Initial Product Expected in Q1 2021”